All forms of amyloidosis are caused by the abnormal folding of proteins in our body’s cells. In the case of wild-type ATTR amyloidosis, normal proteins accumulate but are not cleared from organs, ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment can ...

The prognosis for people with ATTR amyloidosis depends on a range of factors, including the type they have, which organs are impacted, and the kind of treatment they’ve received. In amyloidosis, ...

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. While cardiomyopathy is a ...

Pacing device implants (PDIs) or implantable cardioverter-defibrillators (ICD) may be placed to treat or prevent the consequences of amyloid deposits (heart failure and conduction disturbances) in ...

Acoramidis (Attruby; BridgeBio), a drug that stabilizes transthyretin and has demonstrated benefit on cardiovascular outcomes, has been approved by the US Food and Drug Administration for the ...

AMSTERDAM, the Netherlands—Top-line results of ATTRibute-CM were already known, but a new Hot Line presentation at the European Society of Cardiology (ESC) Congress 2023 delivered more information ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...